Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) hit a new 52-week low on Wednesday. The stock traded as low as $26.56 and last traded at $26.9810, with a volume of 72,622 shares. The stock had previously closed at $27.40.
Analysts Set New Price Targets
IDYA has been the subject of a number of research reports. Stifel Nicolaus started coverage on IDEAYA Biosciences in a report on Wednesday, October 14th. They issued a “buy” rating and a $48.00 price objective for the company. Wedbush boosted their target price on shares of IDEAYA Biosciences from $60.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, November 4th. Wall Street Zen downgraded shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Mizuho dropped their price objective on shares of IDEAYA Biosciences from $44.00 to $39.00 and set an “outperform” rating on the stock in a research note on Monday, November 9th. Finally, Truist Financial restated a “buy” rating and issued a $57.00 price objective (down from $59.00) on shares of IDEAYA Biosciences in a report on Tuesday, November 3rd. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $49.55.
View Our Latest Stock Analysis on IDEAYA Biosciences
IDEAYA Biosciences Stock Down 2.5%
The company has a fifty day simple moving average of $35.05 and a 200 day simple moving average of $33.85. The firm has a market capitalization of $2.58 billion, a P/E ratio of -5.93 and a beta of 0.08.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). IDEAYA Biosciences had a negative return on equity of 39.78% and a negative net margin of 1,157.18%. The company had revenue of $10.24 million during the quarter, compared to analysts’ expectations of $7.58 million. During the same period in the prior year, the company posted $1.33 earnings per share. The company’s revenue was up 14.6% on a year-over-year basis. As a group, equities analysts expect that IDEAYA Biosciences, Inc. will post -4.63 earnings per share for the current fiscal year.
Insider Transactions at IDEAYA Biosciences
In other news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer owned 690,695 shares in the company, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.70% of the company’s stock.
Institutional Trading of IDEAYA Biosciences
Institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP increased its holdings in shares of IDEAYA Biosciences by 95.8% in the 3rd quarter. Allworth Financial LP now owns 883 shares of the company’s stock worth $34,000 after purchasing an additional 432 shares in the last quarter. Aquatic Capital Management LLC lifted its stake in IDEAYA Biosciences by 3,154.0% during the 3rd quarter. Aquatic Capital Management LLC now owns 45,361 shares of the company’s stock valued at $1,743,000 after acquiring an additional 43,967 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 18.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,453,997 shares of the company’s stock valued at $55,863,000 after acquiring an additional 222,383 shares during the last quarter. Jump Financial LLC grew its stake in shares of IDEAYA Biosciences by 326.4% in the third quarter. Jump Financial LLC now owns 239,240 shares of the company’s stock worth $9,192,000 after acquiring an additional 183,131 shares during the period. Finally, Aberdeen Group plc raised its holdings in shares of IDEAYA Biosciences by 5.3% during the third quarter. Aberdeen Group plc now owns 590,777 shares of the company’s stock valued at $22,698,000 after purchasing an additional 29,843 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.
Read More
- Five stocks we like better than IDEAYA Biosciences
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
